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Abstract
Background: Primary pancreatic lymphomas (PPL) are rare tumours of the pancreas. Symptoms,
imaging and tumour markers can mimic pancreatic adenocarcinoma, but they are much more
amenable to treatment. Treatment for PPL remains controversial, particularly the role of surgical
resection.
Methods: Four cases of primary pancreatic lymphoma were identified at Prince of Wales Hospital,
Sydney, Australia. A literature review of cases of PPL reported between 1985 and 2005 was
conducted, and outcomes were contrasted.
Results: All four patients presented with upper abdominal symptoms associated with weight loss.
One case was diagnosed without surgery. No patients underwent pancreatectomy. All patients
were treated with chemotherapy and radiotherapy, and two of four patients received rituximab.
One patient died at 32 months. Three patients are disease free at 15, 25 and 64 months, one after
successful retreatment. Literature review identified a further 103 patients in 11 case series.
Outcomes in our series and other series of chemotherapy and radiotherapy compared favourably
to surgical series.
Conclusion: Biopsy of all pancreatic masses is essential, to exclude potentially curable conditions
such as PPL, and can be performed without laparotomy. Combined multimodality treatment,
utilising chemotherapy and radiotherapy, without surgical resection is advocated but a cooperative
prospective study would lead to further improvement in treatment outcomes.
Background
Primary pancreatic lymphoma (PPL) is rare, comprising
less than 0.5% of pancreatic tumours[1]. To distinguish
PPL from secondary involvement of the pancreas by non-
Hodgkin's lymphoma, Behrns' clinical and diagnostic cri-
teria of PPL include: mass predominantly within the pan-
creas with grossly involved lymph nodes confined to the
peripancreatic region, no palpable superficial lymphaden-
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opathy, no hepatic or splenic involvement, no mediasti-
nal nodal enlargement on chest radiograph, and normal
white cell count [2]. Presenting symptoms are non-spe-
cific, typically including abdominal pain, weight loss,
nausea and vomiting [2]; but also jaundice, acute pancre-
atitis, and small bowel obstruction [3]. PPL can be diffi-
cult to differentiate from pancreatic adenocarcinoma
without definitive pathological diagnosis[3], and correct
diagnosis is crucial given that PPL has differing manage-
ment and usually a much better prognosis. The sizeable
cohort of patients with PPL who are not cured with cur-
rent treatment demands further improvements. Optimal
treatment of PPL remains controversial, particularly the
role of surgery and radiotherapy.
A retrospective analysis of patients with PPL at our institu-
tion was conducted, to examine our treatment outcomes
with modern multimodality therapy. We present a case
series of four patients – one of the few in the recent litera-
ture when newer therapies such as rituximab have become
available – and contrast outcomes with previously pub-
lished case series.
Methods
An electronic search through the medical oncology
department records of Prince of Wales Hospital (Sydney,
Australia) identified four cases of PPL among 481 cases of
non-Hodgkin's lymphoma between 1990 and 2005. Med-
ical records were reviewed, in regards to age, sex, present-
ing symptoms, radiological appearance, histological
diagnosis and method, staging investigations, treatment
regimen and outcome.
Staging was assigned by a modification of the Ann Arbor
classification [4]; accordingly stage IE disease is confined
to the pancreas, and stage IIE disease involves the pan-
creas and peripancreatic nodes. Histological categorisa-
tion was according to the Revised European American
Table 1: Patient characteristics, treatment and outcomes
C a s e  1C a s e  2C a s e  3C a s e  4
A g e 6 47 05 66 1
Sex Male Male Male Male
Presenting Symptoms Abdominal pain, nausea, 
weight loss then jaundice
Vomiting, weight loss Dyspepsia, weight loss Abdominal pain, weight loss 
then jaundice
Delay until diagnosis 5 weeks 3 months 18 months 4 months
Method of diagnosis Endoscopic ultrasound FNA Laparotomy Laparotomy Laparotomy
CT appearance 6 cm pancreatic mass with 
biliary obstruction and 
portal vein involvement
Large peri-pancreatic mass 5 cm pancreatic mass Pancreatic mass and 
peripancreatic lymph nodes
Ca-19.9 level* 500 kU/L 50 kU/L Not available 39 kU/L
Pre-treatment LDH Normal Elevated Normal Elevated
Histology** DLBCL DLBCL Grade II follicular non-
Hodgkins lymphoma
DLBCL
Stage*** IIE IIE IIE IIE
Prognostic index Low-intermediate risk (IPI 2/
5)
Low-intermediate risk (IPI 2/
5)
Low risk (FLIPI 1/5) Low-intermediate risk (IPI 2/
5)
Treatment R-CHOP * 4 then involved-
field RT
CHOP * 3 then involved-
field RT
Involved-field RT then CVP 
then rituximab
3 * CHOP then involved-
field RT
Outcome NED at 23 months Local recurrence at 32 
months post-diagnosis, with 
poor tolerance of 2nd line 
chemotherapy and rapid 
treatment-related death
NED at 25 months Out of field recurrence at 21 
months post diagnosis. 
Salvage chemotherapy and 
autologous SCT. NED at 64 
months from diagnosis
CHOP – Cyclophosphamide, doxorubicin, vincristine, prednisone
CVP – Cyclophosphamide, vincristine, prednisone
DLBCL – diffuse large B-cell non-Hodgkin's lymphoma
FLIPI – Follicular lymphoma international prognostic index [8]
IPI – International Prognostic Index for the Aggressive Non-Hodgkin's Lymphomas [7]
NED – No evidence of disease
R-CHOP – Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone
RT – Radiotherapy
SCT – Stem cell transplantation
* Normal Range 0–50 kU/L
** Histology defined according to REAL classification.[5]
*** Staging defined according to Ann Arbor staging system.[4]BMC Cancer 2006, 6:117 http://www.biomedcentral.com/1471-2407/6/117
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Lymphoma (REAL) classification [5]. Performance status
was defined according to the Eastern Cooperative Oncol-
ogy group (ECOG) scale [6]. The prognosis of patients
was assessed using the criteria of the International Prog-
nostic Index [7] for aggressive lymphomas, and the Follic-
ular Lymphoma International Prognostic Index (FLIPI)
[8] for follicular lymphomas respectively.
Previously reported cases of PPL published between 1985
and 2005 were identified through a Medline search of the
English literature using the keywords of "pancreas" and
"lymphoma". Further case series were identified through
citation review of identified articles. Single case reports,
and cases of stage III/IV disease were excluded.
Results
Case series
Four cases were identified of this rare condition at our
institution. All cases were male, and age ranged from 56
to 70. Summary data is presented in table 1.
Case 1
A 64 year old man presented with a five week history of
right upper quadrant pain, nausea, and jaundice, with five
kilograms of weight loss. Liver function tests demon-
strated biliary obstruction. Serum Ca-19.9 tumour marker
assay was markedly increased at 500 kU/L (normal range
0–40). Abdominal CT demonstrated a 6 cm solid mass
within the head of the pancreas, invading the portal vein,
associated with biliary obstruction, but without lymphad-
enopathy or hepatic involvement (Figure 1). At ERCP a
long lower common bile duct stricture was stented with
prompt relief of biliary obstruction. Although pancreatic
adenocarcinoma was strongly suspected, endoscopic
ultrasound-guided biopsy revealed CD20 positive diffuse
large B cell non-Hodgkin's lymphoma. Staging PET scan
and bone marrow aspirate and trephine (BMAT) noted
uptake in the coeliac nodes, without evidence of wide-
spread dissemination of lymphoma.
Pre-operative assessment avoided the need for exploratory
laparotomy. 4 cycles of CHOP (Cyclophosphamide, Dox-
orubicin, Vincritine, Prednisone) with concurrent rituxi-
mab (anti-CD20 chimeric monoclonal antibody,
Genentech, CA, USA) was administered with complete
response. Chemotherapy was then ceased because of
asymptomatic anthracycline-induced decline in ejection
fraction. Involved field external beam radiotherapy (36
Gray in 20 fractions) was administered. Fifteen months
following diagnosis the patient remains in complete
remission.
Case 2
A 70 year old man described a several month history of inter-
mittent vomiting, anorexia and weight loss, on a back-
ground of chronic renal failure due to polycystic kidney
disease (serum creatinine 450 umol/L; normal range 60–
110 umol/L). MRI (magnetic resonance imaging) of the
abdomen (Figure 2) demonstrated a large confluent mass
lying above the head of the pancreas, posterior to the stom-
Case 2 MRI Figure 2
Case 2 MRI. MRI (magnetic resonance imaging) shows mass 
arising from head of pancreas, as well as hepatic and renal 
cysts.
Case 1 CT Scan Figure 1
Case 1 CT Scan. CT scan of upper abdomen in arterial 
phase shows low density soft tissue in region of pancreatic 
head and posterior to body of pancreas, and biliary stentBMC Cancer 2006, 6:117 http://www.biomedcentral.com/1471-2407/6/117
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ach, as well as prominent renal and hepatic cysts, without
lymphadenopathy or mesenteric vessel involvement. Ca-
19.9 was mildly elevated. CT-guided FNA was non-diagnos-
tic, and endoscopic ultrasound was not available. At surgery
– a risky procedure given his renal impairment – a large
tumour was noted posterior to the duodenum, with bulky
lymphadenopathy and peritoneal seeding. Although pancre-
atic carcinoma or polycystic kidney disease of the pancreas
was suspected, intra-operative frozen section revealed CD20
positive diffuse large B-cell lymphoma (Figure 3 and 4). For-
mal staging with gallium scan and BMAT did not reveal fur-
ther dissemination. Given potential for cure with
chemotherapy and radiotherapy, resection was not per-
formed.
Systemic combination chemotherapy with dose-modified
CHOP was administered, after explanation of risk of sig-
nificant toxicity and treatment-related end-stage renal fail-
ure. Dose-limiting toxicity included neutropaenia,
cardiotoxicity and sensory neuropathy, which required
cessation of treatment after only three of a planned six
cycles. Progress CT scan demonstrated over 50% reduc-
tion in size of the pancreatic mass. Involved field radio-
therapy (45 Gray in 25 fractions) was well tolerated,
inducing radiological complete remission.
Thirty months after diagnosis end-stage renal failure
occurred, requiring hemodialysis. Thirty-two months fol-
lowing diagnosis (23 months following therapy) the
patient suffered symptomatic mediastinal and gastric
recurrence. Second-line combination chemotherapy
(DHAC – carboplatin, doxorubicin, cytosine arabinoside,
dexamethasone) was poorly tolerated, with febrile neu-
tropaenia and grade three gastrointestinal bleeding. The
patient had a limited response, and died a short time later.
Case 3
A 56 year old man presented with progressive dyspepsia
and 12 kg of weight loss over 18 months. Ultrasound and
CT revealed a five cm pancreatic mass involving the trans-
verse colon; without lymphadenopathy, mesenteric vessel
or hepatic involvement. At laparotomy for a planned
Whipple's procedure, histopathology from open biopsy
of the pancreatic mass and adjacent nodes was consistent
with CD20-positive grade II (mixed small and large cell)
follicular lymphoma. PET scan and bone marrow staging
revealed regional nodal involvement. Resection was not
performed.
Treatment consisted of involved field radiotherapy (36 Gy
in 20 fractions), with sequential CVP chemotherapy for
five cycles and sequential rituximab for four cycles.
Restaging confirmed complete response, and the patient
remains in complete remission 25 months following diag-
nosis.
Case 4
A 61 year old man experienced progressive epigastric and
back pain, 12 kg weight loss and then jaundice. Liver func-
tion tests were consistent with biliary obstruction. Ca19.9
was within normal range. CT scan revealed a pancreatic
mass and peripancreatic lymphadenaopthy, without
mesenteric vessel or hepatic involvement. ERCP and inser-
tion of biliary stent relieved obstruction, however biliary
brushings and subsequent FNA were non-diagnostic.
Laparotomy and open biopsy of the peripancreatic lymph
Case 2 Biopsy CD20 stain Figure 4
Case 2 Biopsy CD20 stain. CD20 positive staining of cells, 
consistent with B cell origin (×200)
Case 2 Biopsy Figure 3
Case 2 Biopsy. Histological section shows large mononu-
clear cells, consistent with diffuse large B-cell lymphoma 
(H&E stain, ×200)BMC Cancer 2006, 6:117 http://www.biomedcentral.com/1471-2407/6/117
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nodes revealed CD20 positive diffuse large B-cell lym-
phoma, and resection was not performed.
Treatment consisted of three cycles of CHOP chemother-
apy followed by involved field radiotherapy (42 Gy in 19
fractions). The patient had a complete response to treat-
ment, however relapsed out of field 21 months following
diagnosis (17 months after treatment), with complete
response to second-line ICE chemotherapy, high-dose
BEAM chemotherapy and autologous stem cell transplan-
tation. After 64 months following diagnosis (37 months
from 2nd treatment), the patient remains in remission.
Literature review
Literature review identified 103 additional cases of PPL
from 11 case series. Histopathology; use of successful
non-operative biopsy; use of resection, chemotherapy and
radiation; and outcomes are described in table 2.
High-grade B cell lymphomas were most commonly iden-
tified (45% of cases), followed by low grade B lymphomas
(15%) and other B cell lymphomas (34%). T cell lympho-
mas, although very uncommon (4% of cases), carried a
dismal prognosis. Our series was comparable to other
series with 75% high-grade B cell lymphomas and 5% low
grade lymphomas. Histological diagnosis was established
by non-operative biopsy in 29 of 105 cases (28%),
laparotomy in 69 of 105 cases (65%), and autopsy in 7 of
105 cases (7%). Surgical resection of the tumour was per-
formed in 23 of 107 cases (21%). Chemotherapy was
administered in 80 of 107 cases (75%). Radiotherapy was
administered in 33 of 105 cases (31%).
Comparisons were made between treatment groups.
Without any definitive treatment, results were uniformly
poor with no patients free of disease and poor long-tem
survival. Patients treated with chemotherapy and/or radi-
otherapy – without resection – did not appear to have
worse outcomes than resected patients. Formal statistical
comparison was not able to be performed.
In our series of non-surgical multimodality therapy, three
of four patients were free of disease at time of follow up,
with mean survival 34 months, and 2-year survival of
75%.
Discussion
Our case series illustrates that the clinical presentation of
PPL can be difficult to differentiate from pancreatic aden-
ocarcinoma without definitive pathological diagnosis.
Reliance on symptoms, imaging and tumour markers – in
the absence of definitive pathological diagnosis of sus-
pected pancreatic adenocarcinoma – can potentially result
in the misdiagnosis of a small minority of potentially cur-
able patients. This is important as the prognosis and man-
agement of PPL differs greatly from that of
adenocarcinoma.
Appearances on CT can be helpful to differentiate the two
conditions, but are not definitive[9,10]. Ca19-9 is the
most useful tumour marker in pancreatic carcinoma, but
can be misleading as it may also be elevated in other
malignancies, particularly of the upper gastrointestinal
tract, including PPL as described in case one [11]. Without
definitive pathologic diagnosis, potentially curable condi-
tions such as PPL; as well as other malignancies with more
favourable prognosis, including periampullary, distal
common bile duct, duodenal and mucinous cyst adeno-
carcinomas, may be misdiagnosed[12].
Non-operative evaluation and biopsy of pancreatic
masses can avoid the need for invasive surgery, if condi-
tions such as PPL are found. The majority of cases of PPL
in our literature review required laparotomy for diagnosis,
which may have been avoided with successful non-opera-
tive biopsy and modern combined modality treatment.
Radiological-guided percutaneous FNA of the pancreas is
a very useful technique, which requires experienced radi-
ologists and cytopathologists to obtain a diagnosis on a
small amount of tissue[3]. Endoscopic ultrasound has
greatly improved the accuracy of diagnosis and obtaining
diagnostic tissue [13-18]. Diagnosis of PPL may be
extremely difficult on haematoxylin-eosin stains alone,
and resemble poorly differentiated carcinoma and reticu-
lum cell sarcoma[19], thus immuno-histochemical stains
and flow cytometry are essential[3]. It must be empha-
sised that cytological diagnosis may not be adequate for
diagnosis and categorisation of an abdominal mass, and
tissue biopsy should be considered. In some situations
(including two of our patients with non-diagnostic FNA),
laparotomy may be required for definitive diagnosis.
Treatment of PPL remains controversial – particularly the
role of surgery and radiotherapy – and based on our findings
we do not support routine pancreatectomy. All patients in
our case series received multimodality treatment with both
chemotherapy and radiotherapy, without surgical resection.
Experience from our case series and literature review (table
2) indicates that this modern treatment regime achieves
favourable outcomes, comparable or better than surgical
series, without the morbidity of surgical resection. Most
modern authors would not recommend surgery except when
non-surgical diagnosis is unsuccessful [20-22]. Surgery is
difficult in PPL because tumours are large, and often associ-
ated with an otherwise histologically normal pancreas, car-
rying a high risk of postoperative pancreatic fistula[23].
Technical improvements in pancreatic surgery have led to
reduced peri-operative morbidity and mortality, and in con-
trast Koniaris argues that pancreatectomy should be reevalu-BMC Cancer 2006, 6:117 http://www.biomedcentral.com/1471-2407/6/117
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ated as a method of improving local control and cure
rates[23].
Table 2: Literature review – patient characteristics, treatment and outcomes – abbreviations and reference list
Name 
(Country)
Year n Pathology 
(number 
of cases)
Successful 
non-
operative 
biopsy
Resection Chemo-
therapy
Radio-
therapy
Outcome 
without 
resection, 
chemothe
rapy or RT
Outcomes 
with 
resection
Outcomes with 
chemotherapy 
without 
resection or RT
Outcomes with 
chemotherapy 
and RT without 
resection
Hart USA 1987 14 Histiocytcic 
(9)
Poorly diff 
lymphocytic 
(2)
Well diff 
lymphocytic 
(1)
T cell (1)
Undifferenti
ated (1)
0 of 14 1 of 14 CHOP (14) 1 of 14 0 1 NR
(Received 
CHOP, RT 
NR)
6 alive at mean 32 months (18–48 
months)
2 died within 3 months
5 died at mean 35 months (6–108)
(5 of 13 received RT)
Webb 
USA
1989 2** DLBCL (6)
Follicular 
mixed (2)
Small 
cleaved (1)
1 of 2 MACOP-B (1) 0 of 2 0 1 alive at 95 
months
(Received 
CAMEL, 0 
RT)
1 alive at 21 
months
0
Mansour 
England
1989 12 NR 0 of 12 1 of 12 CHOP (9) 5 of 12 2 died in 
post-op 
period after 
bypass
1 NR
(Received 
chemo, RT 
NR)
4 alive at 3,36,48,84 months
5 died at 2–11 months
(5 of 9 received RT)
Tuchek 
USA
1993 7 NR 0 of 7 0 of 7 CHOP (1)
CVP (1)
CAMEL (1)
0 of 7 4 died – 
mean 
survival 5 
months
0 3 alive at 60,72,96 
months
0
Behrns 
USA
1994 12 DLBCL (7)
Small 
cleaved (2)
Mixed (3)
4 of 12 1 of 12 CHOP (4) 4 of 12 2 relapsed 
or died 
(NR)
1 NR
(Received 
chemo, RT 
NR)
2 died – mean 
survival 13 months
3 died – mean 
survival 26 months
(5 died after RT 
only – mean 
survival 22 months)
Ezzat 
Saudi 
Arabia
1996 5 DLBCL (5) 2 of 5 1 of 5 CHOP (4)
CHOP- Bleo 
(1)
2 of 5 0 1 alive at 23 
months
(Received 
CHOP, 0 
RT)
2 alive at 24,24 
months
2 alive at 30,84 
months
Bouvet 
USA
1997 11 DLBCL (10)
Mixed 
follicular (1)
6 of 11 3 of 11 See legend* 7 of 11 0 3 alive at 
11,13,23 
months
(All received 
CHOP, 
OPEN or 
CHOP-Bleo, 
0 RT)
1 alive at 191 
months
4 alive at 
44,55,67,159 
months
3 died at 12,16,80 
months
Koniaris 
USA
2000 8 DLBCL (7)
Mixed 
follicular (1)
3 of 8 3 of 8 CHOP (6)
MACOP-B (1)
5 of 8 0 3 alive at 
53,62,64 
months
(2 received 
CHOP and 
RT)
1 alive at 24 
months
2 alive at 51,128 
months
2 died at 9,37 
months
Nishimur 
a Japan
2001 19 DLBCL (9)
B 
Immunocyt
oma (2)
B follicular 
(2)
T peripheral 
(3)
T anaplastic 
large (1)
2 of 19 10 of 19 CHOP (5)
Mitomycin (1)
Tegafur (1)
Unspecified 
chemo (1)
0 of 19 7 died at 
1,2,2,3,8,60,
72 months
4 died at 
9,10,11,27 
months
4 alive at 
3,4,12,19 
months
2 ND
(6 received 
chemo, 4 no 
chemo, 0 RT)
2 died at 2,8 
months
0
Nayer 
USA
2004 8 DLBCL (4)
High grade 
B cell (1)
Low grade B 
(2)
Suspicious 
(1)
8 of 8 0 of 8 Chemo (4)
Chemo and 
auto SCT (2)
NR (2)
3 of 8
(2 NR)
0 0 3 alive at 5,6,76 
months
3 alive at 2,7,72 
months
Arcari 
Italy
2005 5 DLBCL (3)
Lymphoplas
macytic (2)
3 of 5 2 of 5 CVP/CHO
P (3)
CHOP (1)
CVP (1)
2 of 5 0 1 alive at 160 
months
1 died at 8 
months
(Received 
CHOP or 
CVP, 0 RT)
1 alive at 60 months
2 died at 67, 88 months
(2 of 3 received RT)
Grimison 
Australia 
[current 
series]
2005 4 DLBCL (3)
Follicular (1)
1 of 4 0 of 4 CHOP (2)
Rituximab- 
CHOP (1)
CVP (1)
4 of 4 0 0 0 1 died 32 months
3 alive 15,25,64 
monthsBMC Cancer 2006, 6:117 http://www.biomedcentral.com/1471-2407/6/117
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It is pertinent to consider the diminishing role of surgery
in other localised extra-nodal lymphoma. Historically, the
treatment of localised gastric non-Hodgkin's lymphoma,
excluding MALT (mucosa-associated lymphoid tissue)-
type lymphomas, was based on surgery – to ensure ade-
quate diagnosis and staging, and maximise survival rates
[24]. Three recent large prospective studies [24-26] and
two smaller randomised controlled trials [27,28] of chem-
otherapy vs. combined surgery and chemotherapy have
reported equivalent survival. Thus the role of surgery in
gastric lymphoma may be limited to rare patients with
acute complications or residual disease following non-
surgical treatment [26,29] In intestinal non-Hodgkin's
lymphoma, following a prospective study there is a trend
away from extensive resection [30]. Localised extraintens-
tinal non-Hodgkins lymphoma has been treated without
surgery for over two decades, following numerous well
conducted prospective clinical trials. These changes in
management illustrate the need for large cooperative pro-
spective studies in PPL, which will better define any bene-
fit of resection, as well as the role of therapies such as
radiotherapy and rituximab.
Radiotherapy has had only limited reported use in the
treatment of PPL (see table 2). Potential concerns about
the safety of radiotherapy in this region may be unneces-
sary, as toxicity has been substantially reduced with three-
dimensional treatment planning and conformal delivery
of radiotherapy[31]. With these modern techniques small
bowel toxicity is minimised, and none of our patients
required radiotherapy interruption. The role of radiother-
apy in early stage high-grade lymphoma remains contro-
versial in a global sense. In localised intermediate and
high-grade non-Hodgkin's lymphoma, chemotherapy
using the CHOP regimen plus adjuvant radiotherapy is
superior to chemotherapy alone[32]. Intensive chemo-
therapy regimens without radiotherapy have been shown
to be superior to CHOP plus involved field radiother-
apy[33]. An important question asks whether the addition
of adjuvant radiotherapy to more intensive chemotherapy
regimens would further improve outcomes[34]. We advo-
cate combined multimodality therapy with both chemo-
therapy and radiotherapy for PPL.
Two of our four patients received rituximab (anti-CD20
chimeric monoclonal antibody, Genentech, CA, USA).
We are not aware of its use in other series of PPL, however
its use has been reported in gastric lymphoma [35], and
evidence exists of its benefit combined with chemother-
apy in other high-grade lymphoma for patients aged over
60[36].
Biliary sepsis is a potential problem of multimodality
therapy in the setting of PPL, due to both the frequent
presence of biliary stents, and the risk of neutropaenia. A
study of endobiliary stents in multimodality therapy of
pancreatic carcinoma reported low rates of complications,
with 15 of 101 cases complicated by occlusion or migra-
tion, and no uncontrolled biliary sepsis or stent-related
death[37]. Another study of patients with malignant bil-
iary obstruction and bile duct stents did not find increased
biliary complications in patients receiving chemother-
apy[38]. Metal stents are superior to plastic stents for
long-term patency [39-41]. Prompt recognition and treat-
ment of biliary complications is important to allow ongo-
Overall 107 
cas
es 
inc. 
cur
rent 
seri
es
Excluding 2 
NR:
29 of 105
23 of 107 80 of 107 Excluding 
2 NR:
33 of 105
Excluding 2 
NR:
0% (0 of 15) 
NED
Mean 13 
months
2YS 13% (2 
of 15)
Excluding 5 
NR:
72% (13 of 
18) NED
Mean 34 
months
2YS 33% (6 
of 18)
57% (36 of 63) 
NED
Mean 38 months
2YS of 62% (28 of 
45) – excludes 18 
NR
*CHOP (1), CHOP-Bleomycin (2), CHOP-OPEN (2), CHOP-Bleomycin, CMED, ESHAP (1), CHOP-Bleomycin, OPEN (1), CHOP, OAP-Bleomycin, MIME (1), CHOP-
Bleomycin, MINE, ESHAP, Autologous SCT (1), IM-Etop, HOP (1), ESHAP, BACOS, MIME (1)
**excludes 7 patients with stage III/IV NHL
BACOS – bleomycin, doxorubicin, cyclophosphamide, vincristine, methylprednisolone
CAMEL – cyclophophamide, adriamycin, vincristine, prednisone Chemo – chemotherapy
CHOP – cyclophosphamide, doxorubicin, vincristine, prednisone
CMED – cyclophosphamide, methotrexate, etoposide, dexamethasone
CVP – cyclophosphamide, vincristine, prednisone
DLBCL – diffuse large Bcell lymphoma
ESHAP – etoposide, methyprednisolone, high-dose cytarabine, cisplatin
HOP – doxorubicin, vincristine, prednisone
IM-etop – ifosfamide, methotrexate, etoposide
MACOP-B
MIME – MESNA, ifosfamide, methotrexate, etoposide
MINE – MESNA, ifosfamide, mitoxantrone, etoposide
NED – no evidence of disease
NR – not reported
OAP-Bleomycin – vincristine, cytarabine, prednisone, bleomycin
OPEN – vincristine, prednisone, etoposide, mitoxantrone
RT – radiotherapy
SCT – stem cell transplantation
References for table 2 – Hart[12], Webb[22], Mansour.[45], Tuchek[47], Behrns.[2], Ezzat[48], Bouvet.[21], Koniaris[23], Nishimura[49], Nayer.[3], Arcari[20]
Table 2: Literature review – patient characteristics, treatment and outcomes – abbreviations and reference list (Continued)BMC Cancer 2006, 6:117 http://www.biomedcentral.com/1471-2407/6/117
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ing therapy, as happened on several occasions to our
patients.
We have examined for any possible association between
polycystic kidney disease and PPL, given the existence of
both conditions in case two. Although polycystic kidney
disease has been associated with pancreatic cystadenoma
and cystadenocarcinoma in a small number of case
reports [42-44], we are not aware of any association with
pancreatic lymphoma.
The study of PPL is limited by the rarity of the condition,
and the consequent lack of randomised trials or large case
series. The comparison of our case series with other series
must be interpreted cautiously, given variable follow-up
(range two – 108 months), incomplete data in some case
series[2,3,12,45], and the inherent publication bias
within case series favouring positive results, as described
by Albrecht[46]. We strongly advocate a multi-centre pro-
spective study of patients with PPL to improve patient out-
comes.
Conclusion
PPL is a rare but potentially curable pancreatic tumour,
and mandates pathological diagnosis of all pancreatic
masses, as its treatment and prognosis differs from aden-
ocarcinoma. Non-operative diagnosis may avoid the need
for surgery, as outcomes with chemotherapy and radio-
therapy – without surgical resection – compare favourably
to surgical series. Nevertheless a sizeable cohort of
patients are not cured with modern therapy, and we advo-
cate a prospective study to further improve treatment out-
comes.
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